SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-028042
Filing Date
2019-08-01
Accepted
2019-08-01 17:16:18
Documents
60
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q JUNE 2019 ntla-10q_20190630.htm   iXBRL 10-Q 2549158
2 EX-31.1 ntla-ex311_8.htm EX-31.1 17030
3 EX-31.2 ntla-ex312_6.htm EX-31.2 17046
4 EX-32.1 ntla-ex321_9.htm EX-32.1 6274
  Complete submission text file 0001564590-19-028042.txt   10153769

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ntla-20190630.xsd EX-101.SCH 50205
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20190630_cal.xml EX-101.CAL 42228
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20190630_def.xml EX-101.DEF 146215
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20190630_lab.xml EX-101.LAB 403079
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20190630_pre.xml EX-101.PRE 290855
10 EXTRACTED XBRL INSTANCE DOCUMENT ntla-10q_20190630_htm.xml XML 2564509
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 19993605
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences